Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Genmab AS (GMAB)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Genmab AS's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
44.88 +0.84    +1.91%
23/09 - Closed. Currency in USD ( Disclaimer )
  • Volume: 418,701
  • Bid/Ask: 43.00 / 44.93
  • Day's Range: 44.50 - 45.04
Type:  Equity
Market:  United States
ISIN:  US3723032062 
CUSIP:  372303206
Genmab AS 44.88 +0.84 +1.91%
Wall Street Falls at Open on Growth Fears; Dow Down 175 Pts
Wall Street Falls at Open on Growth Fears; Dow Down 175 Pts By Investing.com - Sep 07, 2021 1

By Geoffrey Smith  Investing.com -- U.S, stock markets started the holiday-shortened week on a subdued note, as a high-profile downgrade of U.S. growth forecasts weighed on sentiment amid a broad lack...

Genmab AS Earnings, Revenue beat in Q2
Genmab AS Earnings, Revenue beat in Q2 By Investing.com - Aug 11, 2021

Investing.com - Genmab AS reported on Wednesday second quarter earnings that beat analysts' forecasts and revenue that topped expectations. Genmab AS announced earnings per share of $0.0732 on...

Genmab AS Earnings, Revenue beat in Q1
Genmab AS Earnings, Revenue beat in Q1 By Investing.com - May 05, 2021

Investing.com - Genmab AS reported on Wednesday first quarter earnings that beat analysts' forecasts and revenue that topped expectations. Genmab AS announced earnings per share of $0.2682 on...

Genmab AS Earnings miss, Revenue beats In Q4
Genmab AS Earnings miss, Revenue beats In Q4 By Investing.com - Feb 23, 2021

Investing.com - Genmab AS reported on Tuesday fourth quarter earnings that missed analysts' forecasts and revenue that topped expectations. Genmab AS announced earnings per share of $0.1108 on...

Genmab AS Earnings, Revenue beat in Q3
Genmab AS Earnings, Revenue beat in Q3 By Investing.com - Nov 04, 2020

Investing.com - Genmab AS reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations. Genmab AS announced earnings per share of $0.13 on revenue...

Genmab AS Earnings miss, Revenue beats In Q2
Genmab AS Earnings miss, Revenue beats In Q2 By Investing.com - Aug 13, 2020

Investing.com - Genmab AS reported on Wednesday second quarter earnings that missed analysts' forecasts and revenue that topped expectations. Genmab AS announced earnings per share of $0.81 on...

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GMAB Comments

Write your thoughts about Genmab AS
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email